News & Events

In this section

Published originally by Logos Technologies prior to Instem ownership, included here for information purposes

Comprehensive Clinical Development goes into full live production with ALPHADAS®

29th January 2013

Logos Technologies is delighted to report that Comprehensive Clinical Development (CCD) has gone into live, fully validated production with ALPHADAS® at their site in Miramar, Florida.

“The expertise and clinical experience that our team here at Logos Technologies have means we fully understand the needs of clinical sites such as CCD and are able to work with our clients to achieve successful results such as this,” said Giles Wilson CEO at Logos Technologies. ”As well as implementing ALPHADAS we have also developed and provided custom integrations with medical devices at CCD’s request.”

A delighted Chief Information Officer at CCD said, “I need to acknowledge the team at Logos Technologies for their responsiveness/support and knowledge – they have been unbelievable”.

CCD Early Phase has been a leader in providing early phase investigative services since 1994 with outstanding expertise in rapid study startup, complex study methodologies and medical technologies, and special populations.   

ALPHADAS, is an e-Source, pro-active EDC automation system designed specifically for early phase clinical trials which has achieved unsurpassed & peerless success and is currently being used in early phase clinical trials worldwide.  It is a market proven solution that offers a depth of functionality that other systems cannot provide. Logos Technologies continues to invest in ALPHADAS, even further increasing its performance and functionality making it the 'System of Choice' for early phase EDC.

About CCD

Comprehensive Clinical Development is a strategic clinical research partner providing a full range of clinical services in various therapeutic areas with an outstanding record for consistently delivering quality and success on time and within budget. Comprehensive holds a solid track record of collecting early efficacy data across various patient populations, and offers distinct capabilities in clinical research. 

Press Contact:

Angela King